Skip to main content
. Author manuscript; available in PMC: 2021 Jan 31.
Published in final edited form as: Neuroepidemiology. 2020 Jan 31;54(3):272–280. doi: 10.1159/000505874

Table 4:

Studies comparing harmane concentrations in ET cases and controls

Authors (location) ET (all) Definite ET Probable ET Possible ET Control
Louis et al 2002 [12]
(New York)
5.21 g−10/ml (n = 100)
p = 0.005
2.28 g−10/ml (n = 100)
Louis et al 2005 [15]
(New York)
Log harmane = 0.61 ± 0.67 g−10/ml (n = 106)
p = 0.035
Log harmane = 0.74 ± 0.69 g−10/ml (n = 38) Log harmane = 0.56 ± 0.67 g−10/ml (n = 53) Log harmane = 0.48 ± 0.64 g−10/ml (n = 15) Log harmane = 0.43 ± 0.72 g−10/ml (n = 161)
Louis et al 2008 [13]
(New York)
2.61 g−10/ml (n = 150)
p = 0.016
1.82 g−10/ml (n = 135)
Louis et al 2013 [14]
(Madrid)
2.90 g−10/ml in familial ET (n = 62)

2.41 g−10/ml in sporadic ET (n = 68)
p = 0.049 a
2.09 g−10/ml (n = 135)
Current study 2019
(Faroe Islands)
1.74 g−10/ml (n = 26)
p = 0.92
4.13 g−10/ml (n = 3)
p = 0.126
2.28 g−10/ml (n = 12)
p = 0.91
1.27 g−10/ml (n = 11)
p = 0.28
1.53 (n = 196)

Values are median harmane unless otherwise specified as log harmane.

a

in an adjusted logistic regression model comparing familial ET to controls.

p values show comparisons with controls.